This has been the story behind the current move, but it seems bulls have started to capitalize, with the stock easing from a $6.60 swing high to the $6.30 mark where it is trading at the time of writing.
Actinium Pharma, like most pharma companies, trades mainly on medical advances and applications, and once these happen, the bulls are in for a field day. Update: ATNM stock is encountering some profit-taking after the huge spike seen in Tuesday's premarket on the breakout news of leukemia treatment deal. Some deceleration might be in order for the rest of the week and that puts a focus back on the old daily resistance of 5.65. On the monthly chart, this is a 50% mean reversion of the monthly bearish impulse.
However, the bias might be with the bears at this juncture considering the mitigation that has taken place to the upside and the fact that the price closed around a well-defined structure as per the weekly chart. The daily chart has left an incredibly wide-ranged doji on the chart of some 172 ticks. Update: ATNM stock gapped and is yet to mitigate the closing levels of the prior day which makes for a highly unpredictable technical outlook for the remainder of the week. ATNM is to receive $35 million upfront from Immedica.
0 kommentar(er)
